HIV Drug Suit Against Gilead, BMS And Janssen Trimmed

Law360 (July 29, 2020, 10:33 PM EDT) -- A California federal judge dismissed attempts to revive allegations of an antitrust conspiracy involving Gilead, Bristol-Myers Squibb and Janssen Pharmaceuticals to block generic competition and keep HIV medication prices artificially high in a decision unsealed Wednesday that nevertheless left intact key parts of the complaint.

U.S. District Judge Edward M. Chen gave the AIDS activists and consumers pursuing the suit no further chances to amend their allegations of an overarching conspiracy involving all three drug companies. Also tossed with prejudice, in the decision first issued under seal last week, are their additional liability theories based on royalties allegedly paid after patents expired,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!